Autologous Stem Cell Transplantation (ASCT)
Treatment for Multiple Myeloma
Typical Dosage: High-dose Melphalan (e.g., 200 mg/m² IV) single dose
Effectiveness
90%
Safety Score
25%
Clinical Trials
144
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
High-dose Melphalan (e.g., 200 mg/m² IV) single dose
Time to Effect
3-6 months
Treatment Duration
Initial phase 1-2 months, then maintenance for years
Evidence Quality
HIGHConfidence Score
94%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$120,000
Side Effect Mgmt:$25,000
Total Annual:$150,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$130,000/QALY
QALYs Gained
3
Outcome-Based Costs
Cost per Responder
$176,471
Cost per Remission
$250,000
Comparison vs Conventional Chemotherapy without transplant
Cost Difference
+$70,000/year
More expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
No dominance
Autologous Stem Cell Transplantation (ASCT) Outcomes
for Multiple Myeloma
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+85%
Remission Rate
+60%
Common Side Effects
Myelosuppression (severe neutropenia, thrombocytopenia)
+90%
Mucositis
+80%
Infections (bacterial, viral, fungal)
+60%
Fatigue
+80%
Nausea/Vomiting/Diarrhea
+60%
Active Clinical Trials
12 active trials recruiting for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
NCT06963866NOT YET RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Xuzhou, China
Started: May 1, 2025
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
NCT06463717RECRUITING
210 participants
OBSERVATIONAL
Hangzhou, China
Started: Dec 1, 2023
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
NCT05632380RECRUITINGPHASE1, PHASE2
20 participants
INTERVENTIONAL
Tianjin, China
Started: Jul 14, 2022
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
NCT06974786RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Birmingham, United States +10 more
Started: Aug 8, 2025
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
NCT03562169RECRUITINGPHASE3
406 participants
INTERVENTIONAL
Aberdeen, United Kingdom +90 more
Started: Mar 20, 2017
CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?
NCT07070934NOT YET RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Started: Jul 15, 2025
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
NCT07106710RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Tianjin, China
Started: Aug 15, 2025
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
NCT05271630ACTIVE NOT RECRUITING
69 participants
OBSERVATIONAL
Tampa, United States
Started: Apr 20, 2022
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
NCT07106684RECRUITINGPHASE2
20 participants
INTERVENTIONAL
Tianjin, China
Started: Aug 9, 2025
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
NCT07735637RECRUITINGPHASE3
750 participants
INTERVENTIONAL
Gilbert, United States +113 more
Started: Sep 24, 2026
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT03346135ACTIVE NOT RECRUITINGPHASE2
31 participants
INTERVENTIONAL
Duarte, United States +1 more
Started: Jan 6, 2020
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
NCT07903272NOT YET RECRUITINGPHASE3
1K participants
INTERVENTIONAL
Started: Dec 14, 2026
Completed Clinical Trials
3 completed trials for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma
NCT01852799COMPLETEDPHASE2
18 participants
INTERVENTIONAL
Shanghai, China
Started: Dec 1, 2012
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
NCT03477539COMPLETEDPHASE2
49 participants
INTERVENTIONAL
Jacksonville, United States
Started: Apr 9, 2018
Stem Cell Transplantation for Patients With Multiple Myeloma
NCT01526096COMPLETEDPHASE1
30 participants
INTERVENTIONAL
Chicago, United States
Started: Jul 12, 2011
Showing 20 of 150 total trials